Shares of Moderna Inc.
MRNA,
+5.82%

gained 4.7% in trading on Friday after the company said that European regulators recommended authorizing its COVID-19 vaccine for teens as young as 12 years old. The European Medicines Agency’s Committee for Medicinal Products for Human Use issued the recommendation; next up will be the final decision from the European Commission. Moderna’s shot has not yet been authorized for teens in the U.S. The company’s shares have soared 223.2% so far this year, while the S&P 500
SPX,
+1.03%

is up 16.3%.

LEAVE A REPLY

Please enter your comment!
Please enter your name here